Combo UTI drug can now treat costly pneumoniasFDA approved Allergan's supplemental New Drug Application (sNDA) to expand the approved use of ceftazidime and avibactam (Avycaz) to include 2 types of pneumonia.
Meta-analysis on oocyte donation and perinatal outcomesA systematic review and meta-analysis suggests that in pregnancies conceived via assisted reproduction, risk of adverse perinatal outcomes may be higher with donated than with autologous oocytes. Plus: Do post-cesarean antibiotics reduce infections in obese women? Also: Researchers believe they have identified the genes associated with preterm delivery.
Shrinking insurance formulary limits Rx optionsDermatology is truly unique in patient satisfaction, but I am concerned that our ability to deliver this high level of performance is being eroded by factors beyond our control. learn more
Rosacea: Newer topical therapies are effective and well-tolerated
Rosacea: Newer topical therapies are effective and well-toleratedEmerging therapies for rosacea have a favorable side effect profile and address specific symptoms of the condition; brimonidine, for example, addresses background erythema while ivermectin addresses the papules and pustules.
FDA approves new antibacterial drug AvycazFDA has approved ceftazidime-avibactam (Avycaz, Actavis and Forest), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.
Pharmacy review: Metronidazole and adverse drug reactionsA summary of drug-drug interactions and adverse drug reactions connected with metronidazole, a drug widely used in medical and dental practices to counter anaerobic bacteria, amoebae, and parasitic infections.
Shortage of IV metronidazole antibiotic prompts indication-specific alternativesThere has been a recent national backorder of iv Metronidazole (Flagyl) due to manufacturing delays with Hospira. As a result of this delay Hospira has not been able to provide a tentative timeline or estimate date of when IV metronidazole will be available to purchasers/buyers once again. While this situation plays out, there are general management strategies that might be implemented based on the facility.